SAVA
Cassava Sciences Inc
-13.96%
$29.88 - $25.71
Feb 7th 2023 - Mar 21st 2023
Mar, 15, 2023
$SAVA βTreatment also eased depression and dementi... See more
Feb, 6, 2023
Simufilam reduced dementia-related behavior at 9 m... See more
HTGM
HTG Molecular Diagnostics Inc
-37.26%
$4.67 - $2.93
Feb 7th 2023 - Mar 21st 2023
Jan, 20, 2023
Monday morning pre-market screamer π± candidates: ... See more
Dec, 20, 2022
SIMILAR SETUP TO $AMAM, $HTGM, $APVO, $APCX Vo... See more
PHVS
Pharvaris NV
-30.10%
$9.60 - $6.71
Feb 7th 2023 - Mar 21st 2023
Dec, 10, 2022
$PHAR Good news for competitor Pharvaris $PHVS, ... See more
Dec, 9, 2022
$PHVS Look at this company, this could be Athenex ... See more
Mar, 15, 2023
$SAVA βTreatment also eased depression and dementia-related behaviors in patients, two exploratory trial goals, and simufilam was found to be safe and well tolerated.β
Feb, 6, 2023
Simufilam reduced dementia-related behavior at 9 months on the Neuropsychiatric Inventory (NPI), a clinical tool widely used to measure changes in dementia-related behavior.
Feb, 1, 2023
The open label study is a true gift which gives us insight on both health and benefit issues and the med looks great on both counts.
Jan, 17, 2023
$SAVA September 3rd 2021 Remi Barbier said, "I truly believe Cassava Sciences is one clinical program away from greatness.
Jan, 6, 2023
$SAVA Per press release dec 6 2022, Remi stated administration of drug for OL study completed and he is "THRILLED" with the clinical development, or what he see to this date.
Jan, 4, 2023
$SAVA , VERA announced positive phase 2b results meeting primary end point.
Dec, 27, 2022
My prediction: Phase 2 Unbelievable results FDA fast track Phase 3 - go ahead Patients receive sava Market cap 40 B by 2024 Rising to 200 Billion by 2026 Game changer - the only drug in the world to help patients
Jan, 20, 2023
Monday morning pre-market screamer π± candidates: π¨π¨π¨ππππ₯π₯π₯ $TCBP Phase 2 update still pending-huge potential on this nano float $BOXD over $1 easy $ALLR PT $.50 $HTGM sheβs ready for another big run This week was very good to me.
Dec, 20, 2022
SIMILAR SETUP TO $AMAM, $HTGM, $APVO, $APCX Volume increasing since last week β Low float recent IPO β Strong future trial pipeline β Time for the next leg up towards IPO price!
Dec, 11, 2022
SHOULD be some awesome opportunities this week, study study study!
Dec, 9, 2022
$ATNM positive news in their acute myeloid leukemia trials ππΌ 53% 1-year Overall Survival and 32% 2-year Overall Survival are approximately double outcomes with current approaches It's time to get in before we blast off to $12+ next!
Dec, 10, 2022
$PHAR Good news for competitor Pharvaris $PHVS, published interim results of the oral on demand threatment Phase II study which are good!
Dec, 9, 2022
$PHVS Look at this company, this could be Athenex in 2 weeks.. this went up 400% in one day on positive phase 2 data.
Dec, 9, 2022
$LXRX $PHVS goes up 340% on phase 1/2 top line read out
Dec, 9, 2022
$PHVS Trials blocked in US with drug on clinical hold and this goes up 340%.
Dec, 9, 2022
this stock was forever doing nothing languishing at a range of $2 to $3 then all of a sudden, they announce great clinical results and BAMM the stock goes up 339% in ONE DAY!! .
Dec, 8, 2022
Thatβs how these successful trials run %wise.
Dec, 8, 2022
460k float, amazing news on trial commencement
Dec, 8, 2022
$PHVS what a run on phase 2 results, good short here